Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33145 | 0.76 | ALDH1A1 (0.43) | ALDH1A1LMNACYP1A2CYP2C19TDP1 | |
| SCHEMBL11936455 | 0.76 | CYP1A2 (0.38) | ALDH1A1LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL9051621 | 0.74 | ALDH1A1 (0.35) | ALDH1A1LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL4383250 | 0.74 | ALDH1A1 (0.35) | ALDH1A1LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL10920679 | 0.72 | CYP1A2 (0.44) | ALDH1A1LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL3784384 | 0.70 | NOS3 (0.33) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31084638 | 0.69 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL9680459 | 0.69 | CYP1A2 (0.33) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL10637349 | 0.67 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL8975792 | 0.66 | CYP2C19 (0.36) | ALDH1A1LMNACYP1A2CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | ALDH1A1 1007/4885LMNA 4311/4885CYP1A2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.